ST Wanbang announced on July 13 that it is expected to achieve net profit of 65 million yuan to 90 million yuan in the first half of 2026, an increase of 382.79% to 568.47% over the previous year. According to the company, the main reason for the change in performance during the reporting period was the initial results of the company's strategic development and transformation from generic drugs to innovative drugs, and the innovative drug's external licensing business progressed, bringing new performance growth points; the company promoted fine management, optimized product structure, adjusted market layout, and helped promote key new potential varieties in the future; at the same time, the company increased investment in innovative drug research and development, and continued promotion of policies such as procurement and bidding, resulting in a combination of changes in the company's profit.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.